142 related articles for article (PubMed ID: 9069443)
1. Homocysteine - a new arteriosclerotic risk factor in end-stage renal failure.
Zidek W
Nephron; 1997; 75(3):249-50. PubMed ID: 9069443
[No Abstract] [Full Text] [Related]
2. Hyperhomocysteinaemia: a role in the accelerated atherogenesis of chronic renal failure?
Janssen MJ; van den Berg M; Stehouwer CD; Boers GH
Neth J Med; 1995 May; 46(5):244-51. PubMed ID: 7783827
[TBL] [Abstract][Full Text] [Related]
3. Evidence of altered homocysteine metabolism in chronic renal failure.
Henning BF; Riezler R; Tepel M; Langer K; Raidt H; Graefe U; Zidek W
Nephron; 1999; 83(4):314-22. PubMed ID: 10575293
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine and renal disease.
van Guldener C; Robinson K
Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849
[TBL] [Abstract][Full Text] [Related]
5. Homocysteinemia and vascular disease in end-stage renal disease.
Dennis VW; Robinson K
Kidney Int Suppl; 1996 Dec; 57():S11-7. PubMed ID: 8941916
[TBL] [Abstract][Full Text] [Related]
6. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid.
Motulsky AG
Am J Hum Genet; 1996 Jan; 58(1):17-20. PubMed ID: 8554053
[No Abstract] [Full Text] [Related]
7. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease.
Stam F; van Guldener C; Ter Wee PM; Jakobs C; de Meer K; Stehouwer CD
Kidney Int; 2005 Jan; 67(1):259-64. PubMed ID: 15610249
[TBL] [Abstract][Full Text] [Related]
8. Variations in the lipid profile of patients with chronic renal failure, treated with folic acid.
de Gómez Dumm NT; Giammona AM; Touceda LA
Int J Vitam Nutr Res; 2003 May; 73(3):215-20. PubMed ID: 12847999
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease.
McGregor D; Shand B; Lynn K
Nephron; 2000 Jul; 85(3):215-20. PubMed ID: 10867536
[TBL] [Abstract][Full Text] [Related]
10. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein.
Busch M; Franke S; Müller A; Wolf M; Gerth J; Ott U; Niwa T; Stein G
Kidney Int; 2004 Jul; 66(1):338-47. PubMed ID: 15200442
[TBL] [Abstract][Full Text] [Related]
11. [Homocysteine as a nonlipid factor in the pathogenesis of atherosclerosis].
Magott M
Postepy Hig Med Dosw; 1998; 52(3):259-67. PubMed ID: 9789435
[TBL] [Abstract][Full Text] [Related]
12. Renal homocysteine metabolism.
House JD; Brosnan ME; Brosnan JT
Contrib Nephrol; 1997; 121():79-84. PubMed ID: 9336701
[No Abstract] [Full Text] [Related]
13. Hyperhomocysteinaemia and end stage renal disease.
Gupta A; Robinson K
J Nephrol; 1997; 10(2):77-84. PubMed ID: 9238614
[TBL] [Abstract][Full Text] [Related]
14. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
[TBL] [Abstract][Full Text] [Related]
15. Homocysteine and chronic renal failure.
Hannedouche TP; Kunz K; Muller S; Chantrel F
Adv Nephrol Necker Hosp; 1998; 28():287-310. PubMed ID: 9889995
[No Abstract] [Full Text] [Related]
16. Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin.
Naruszewicz M; Klinke M; Dziewanowski K; Staniewicz A; Bukowska H
Metabolism; 2001 Feb; 50(2):131-4. PubMed ID: 11229418
[TBL] [Abstract][Full Text] [Related]
17. [Homocysteine--a risk factor for atherosclerosis].
Debreceni L
Orv Hetil; 2001 Jul; 142(27):1439-44. PubMed ID: 11481906
[TBL] [Abstract][Full Text] [Related]
18. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?
van Guldener C
Nephrol Dial Transplant; 2006 May; 21(5):1161-6. PubMed ID: 16490741
[No Abstract] [Full Text] [Related]
19. Homocysteine and atherothrombosis.
Welch GN; Loscalzo J
N Engl J Med; 1998 Apr; 338(15):1042-50. PubMed ID: 9535670
[No Abstract] [Full Text] [Related]
20. Hyperhomocysteinemia as a cause of vascular occlusion in end-stage-renal disease.
Tamura T; Bergman SM; Morgan SL
Int J Artif Organs; 1998 Feb; 21(2):72-4. PubMed ID: 9569127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
